STOCK TITAN
  1. Home
  2. News
  3. PTPI

Petros Pharmaceuticals Inc - PTPI STOCK NEWS

Welcome to our dedicated news page for Petros Pharmaceuticals (Ticker: PTPI), a resource for investors and traders seeking the latest updates and insights on Petros Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Petros Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Petros Pharmaceuticals's position in the market.

News
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
Rhea-AI Summary
Petros Pharmaceuticals, Inc. (PTPI) receives positive feedback from the FDA for its technology component in pursuit of OTC status for STENDRA (avanafil). The FDA acknowledged the technology's addressing of concerns related to the PDE5 inhibitor class, particularly for nitrate-using patients. The Company's President sees this as a significant step towards achieving OTC status, with ongoing studies and guidance from the FDA shaping future development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.96%
Tags
none
-
News
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Rhea-AI Summary
Petros Pharmaceuticals, Inc. (PTPI) announces positive results of a self-selection study comparing the use of a Drug Facts Label alone to a DFL in combination with a web app. The study shows significant benefits of technology assistance in an OTC setting, particularly for nitrate users. The company aims to provide compelling evidence to the FDA for nonprescription use of STENDRA® (avanafil) as an OTC option for erectile dysfunction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.57%
Tags
clinical trial
-
News
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
Rhea-AI Summary
Petros Pharmaceuticals, Inc. (PTPI) initiates an AI integrated Human Factors Study to enhance self-screening for STENDRA, aiming for OTC status. The collaboration with a software developer led to the successful launch of an AI tool integrated into the company's web app. The study, overseen by Fady Boctor, focuses on optimizing the safe administration of STENDRA and meeting FDA requirements. The Human Factors Study aims to evaluate the web tool's safety and effectiveness for users, potentially paving the way for STENDRA to become the first OTC erectile dysfunction medication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
AI
News
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
Rhea-AI Summary
Petros Pharmaceuticals, Inc. partners with a leading AI software provider to integrate technology for self-screening to bring STENDRA over the counter, aiming to enhance consumer access to medication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
AI
-
News
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
Rhea-AI Summary
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) has scheduled two meetings with the FDA to review the progress of developing STENDRA as the first PDE-5 inhibitor approved for over-the-counter use. The FDA has requested a listen-only meeting to review the app for improved productivity ahead of a Type C meeting on March 26, 2024, to discuss the development of the digital app and protocols for upcoming studies. Petros believes these meetings highlight the significant progress made in achieving OTC status for STENDRA and demonstrate the FDA's interest in the nonprescription development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
none
-
News
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
Rhea-AI Summary
Petros Pharmaceuticals, Inc. announces successful completion of a Phase 2 equivalent Self-Selection Study (SSS) for STENDRA, with technology-enabled subjects correctly self-selecting to use the medication at a rate of over 78%, compared to 56% using the Drug Facts Label alone. The company plans to aggressively pursue a larger SSS cohort and continue discussions with the FDA for a viable pathway to over-the-counter (OTC) status. The study results have informed the development of the next phase of the study, and the company looks forward to providing updates on further development and collaboration with the FDA in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
clinical trial
News
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
Rhea-AI Summary
Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) completes Human Factors Study for STENDRA OTC approval
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.33%
Tags
none
-
News
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider
Rhea-AI Summary
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) partners with Idea Evolver to develop an application for Rx-to-OTC switch for STENDRA® (avanafil), an erectile dysfunction drug. This partnership aims to enhance the self-selection process for potential OTC approval, leveraging IE's experience in successful Actual Use Trials and technology-enabled prescription to OTC switch clinical studies. Petros looks forward to further collaboration with potential partners and the FDA to refine the process for STENDRA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.33%
Tags
partnership
-
News
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider
Rhea-AI Summary
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) partners with Idea Evolver (IE) to develop a technology platform for the Rx-to-OTC switch of its erectile dysfunction drug STENDRA® (avanafil). Idea Evolver is the only provider to successfully complete an Actual Use Trial for FDA review for Rx-to-OTC Switch Approval, and the partnership aims to enhance the self-selection process with potential AI/machine learning components.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
partnership
News
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)
Rhea-AI Summary
Petros Pharmaceuticals announces the development of a new AI/machine learning tool to enhance the self-selection process for its erectile dysfunction drug STENDRA. The technology will be integrated into self-selection studies and follow FDA recommendations. The company plans to collaborate with third-party technology partners for the completion of the tool.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
clinical trial
Stock PTPI logo
Petros Pharmaceuticals Inc

Nasdaq:PTPI

PTPI Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PTPI Stock Data

5.73M
6.20M
11.8%
1.7%
2.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Sacramento

About PTPI

at petros, we are bringing new approaches to the most challenging conditions in men's health. we seek to understand the various health phases throughout a man’s journey. we collaborate with researchers, scientists, medical thought leaders and payers to ensure our therapies aid in restoring men’s body function to vitality.